0000899243-19-003668.txt : 20190214 0000899243-19-003668.hdr.sgml : 20190214 20190214174521 ACCESSION NUMBER: 0000899243-19-003668 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190212 FILED AS OF DATE: 20190214 DATE AS OF CHANGE: 20190214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STARR KEVIN P CENTRAL INDEX KEY: 0001192603 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36544 FILM NUMBER: 19608762 MAIL ADDRESS: STREET 1: 29 NEWBURY STREET STREET 2: 3RD FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sage Therapeutics, Inc. CENTRAL INDEX KEY: 0001597553 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-299-8380 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-12 0 0001597553 Sage Therapeutics, Inc. SAGE 0001192603 STARR KEVIN P C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2019-02-12 4 S 0 0 0.00 D 0 I See Footnote Common Stock 302817 D On February 12, 2019, Third Rock Ventures II, L.P. ("TRV II") sold 37,362 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $153.60 to $154.51, inclusive, at a weighted average price per share of $154.2096. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Following the reported transaction, TRV II held zero shares of Common Stock of the Issuer. These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin, Kevin Starr ("Starr") and Dr. Robert Tepper. Due to an ethical wall between Mr. Starr and each of TRV II, TRV GP II and TRV GP II LLC that prevents (i) the sharing of information related to the Issuer between Mr. Starr and the foregoing funds and their respective representatives and (ii) participation in investment decisions with respect to the common stock of the Issuer held by TRV II, Starr disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. /s/ Kevin Gillis, as attorney-in-fact for Kevin Starr 2019-02-14